1. Home
  2. GBIO vs CELU Comparison

GBIO vs CELU Comparison

Compare GBIO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.40

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.24

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBIO
CELU
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.3M
34.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GBIO
CELU
Price
$5.40
$1.24
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$8.88
$6.00
AVG Volume (30 Days)
72.2K
84.7K
Earning Date
11-05-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,270,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$1.00
52 Week High
$11.90
$4.35

Technical Indicators

Market Signals
Indicator
GBIO
CELU
Relative Strength Index (RSI) 45.94 38.58
Support Level $5.31 $1.20
Resistance Level $5.77 $1.31
Average True Range (ATR) 0.19 0.12
MACD -0.01 0.01
Stochastic Oscillator 23.08 52.13

Price Performance

Historical Comparison
GBIO
CELU

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: